If you would like to submit a blog post for consideration, please email firstname.lastname@example.org
Modern therapies for cutaneous lymphomas were a topic of discussion at the European Academy of Dermatology and Venereology 2017 Congress, which was held in Geneva in September 2017. Continue reading “Cutaneous Lymphomas: New Therapies in Development”
In this month’s skin cancer update video, Associate Professor Giuseppe Argenziano discusses which adjuvant therapies are most effective in the treatment of advanced melanoma.
In stage 3 melanoma patients who have their primary tumour surgically excised, five-year recurrence rates are 70 percent in patients who receive no adjuvant therapy; 64 percent in patients who receive Interferon; 59 percent in patients who receive Ipilimumab; 38 percent in patients who receive Nivolumab; and 37 percent in patients who receive a combination of target therapies. Continue reading “Skin Cancer Update with A/Prof Giuseppe Argenziano [November]”
A ‘groundbreaking’ immunotherapy drug is helping patients overcome advanced non-melanoma skin cancer.
Cemiplimab is being used at Sir Charles Gaidner Hospital in Perth as part of an international trial. Oncologist Annette Lim, who runs the trial, says most patients have responded with encouraging results.
There were strict criteria for patients to enter the trial, but early results suggest the drug could be a game-changer for non-melanoma skin cancer sufferers. Continue reading “Groundbreaking Immunotherapy Drug Beats Skin Cancer”
One of the greatest hurdles in our fight against cancer can be our own immune system, as it often self-sabotages the body’s attempts to fight invading tumours. Researchers from the University of Bonn have recently found a way to get around this immune response, using immunotherapy to achieve a significant delay in cancer growth, which thereby allows cancer sufferers to live longer as the progression of their disease is slowed down. Continue reading “Slowing Down Cancer with Immunotherapy Breakthrough”
The breakthrough PD-L1 inhibitor Avelumab (Bavencio) has been approved by the Japanese Ministry of Health, Labor and Welfare for use in Japanese patients with metastatic Merkel cell carcinoma. It is the first curative treatment for unresectable Merkel cell carcinoma and first anti-PD-L1 agent to be approved in Asia, after receiving its first global approval in the US in March and in Europe in September.
Skin cancer doctors and dermatologists may be tempted to over-treat patients with minor skin cancers in order to make a financial profit for performing higher-cost procedures, according to a symposium focusing on controversies in dermatology.
A presentation entitled “Inconvenient Truths in Skin Cancer Care” was delivered at the 26th European Academy of Dermatology and Venereology Congress by Dr Tamar Nijsten from Erasmus Medical Center in the Netherlands. The presentation highlighted concerns that dermatologists and skin physicians and might perform unnecessary treatments on minor skin cancers such as basal cell carcinoma, or prescribe high-cost drugs offering no advantage over generic-brand counterparts, because these approaches financially benefit the physicians.
This month’s research article is a scholarly review from the British Journal of Dermatology. The topic of the article is actinic keratosis (AK), which is such a common condition – and $1 billion is spent in the US each year treating it. Continue reading “Treating Actinic Keratosis In Primary Care”
The outcomes of a five-year trial investigating the efficacy and safety of the combination of a BRAF inhibitor and a MEK inhibitor treatment for advanced melanoma were recently presented at the Annual Meeting of the American Society of Clinical Oncology in Chicago.
Around 40 percent of patients with advanced melanoma have BRAF-mutations. While it has been known for some time that the combination of BRAF and a MEK inhibitor improves the clinical outcomes for patients with BRAF mutant metastatic melanoma compared with single-agent BRAF inhibition, this was the longest follow-up to date of any randomised trial investigating the treatment combination.
Vitamin B3 could potentially help prevent melanoma in people most at risk of developing the deadly skin cancer, according to a paper published in the Photodermatology, Photoimmunology & Photomedicine journal.
The paper’s author, Dr Gary Halliday, wrote that nicotinamide (or vitamin B3), was shown to reduce the incidence of non-melanoma skin cancer in high-risk individuals in a clinical trial called ONTRAC.
The Professor of Dermatology at the University of Sydney believes it would be worthwhile to further determine whether the vitamin can help prevent melanoma in high-risk patients such as outdoor workers, people with fair skin, and those aged over 40.
Dr Halliday said that vitamin B3 ought to be investigated as an inexpensive way of preventing the disease in people who are most susceptible to developing it, since nicotinamide has been proven to enhance DNA repair and reduce inflammation caused by UV radiation.
While such a clinical trial would be welcomed, it is important to await the results of a study before recommending vitamin B3 as a preventative measure for melanoma, which is the fourth most common cancer in Australia.
(10 August 2017) Vitamin B may help prevent melanoma. SBS.
Interested in skin cancer medicine?
The HealthCert Professional Diploma programs offer foundation to advanced training in skin cancer medicine, skin cancer surgery or dermoscopy and provide an essential step towards subspecialisation. All programs are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The programs are delivered online and/or face-to-face across most major cities of Australia.
In the short video below, Professor Wilkinson speaks about the Skin Cancer Medicine course which has been purpose-built to help busy general practitioners acquire the fundamental skills they need to manage skin cancer with confidence and feel safe in their practice. Please take the opportunity to learn more about Australia’s leading professionally accredited skin cancer education program. Continue reading “Professional Certificate of Skin Cancer Medicine with Prof David Wilkinson”